We've now run our medical weight loss program with both Semaglutide and Tirzepatide for over three years. Patients ask, often, which one we recommend — and the honest answer is that we recommend both, because they suit different patients differently and each has trade-offs. Here is how we actually decide between them.
Mechanism
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 + GIP receptor agonist — the 'GIP' adds a second incretin pathway. In published clinical trials, Tirzepatide produces somewhat greater average weight loss (≈21% vs ≈15% in head-to-head comparisons). That difference is real but not as dramatic as some marketing suggests.
Side effects
Both medications most commonly produce nausea and GI symptoms, especially during dose escalation. Tirzepatide tends to have slightly less GI burden in our patient population — which has, anecdotally, been the bigger differentiator than the weight-loss numbers. Patients who tried Semaglutide and dropped due to nausea often tolerate Tirzepatide.
Cost
Tirzepatide is more expensive — both for branded versions and through compounding pharmacies. The price difference at our clinic is about $200/month sustained. For some patients, this matters; for others, it doesn't.
Who we recommend each for
- Semaglutide first-line for most patients — well-validated, well-understood, lower cost.
- Tirzepatide for patients with prior GI sensitivity to Semaglutide.
- Tirzepatide for patients with significant insulin resistance or pre-diabetes (the GIP component).
- Either for patients who are well-supported, doing the nutrition work, and just need the appetite-regulation tool.
These medications are tools, not magic. The patients who do best are the ones who use the appetite suppression as the window to rebuild eating habits — not the ones who treat it as a license to maintain prior patterns at lower volumes.